Notice of Results

    Notice of results

Cambridge, UK and Cambridge, Massachusetts - 15 January 2004 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its preliminary results for
year ended 31 December 2003 on Tuesday, 2 March 2004.

The results announcement will be released at 7.00 am GMT. A briefing and
conference call for analysts will be held at 9.30 am GMT. An audio webcast of
the call will also be available via Acambis' website at www.acambis.com.

                                    -ends-                                     

Enquiries:

Acambis plc                                                                    
                                                                               
Lyndsay Wright, Director of              Tel: [phone]             
Communications                                                                 
                                                                               
Financial Dynamics                                                             
                                                                               
Mo Noonan                                Tel: [phone]             

About Acambis

Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing a second-generation smallpox vaccine which is
currently undergoing clinical trials and, under a unique arrangement given the
threat of smallpox being used as a bioterrorist weapon, is manufacturing
emergency-use stockpiles of this investigational vaccine for the US Government
and other governments around the world. Acambis is establishing a travel
vaccines franchise through its US-based subsidiary Berna Products Corporation,
which markets Vivotif®, the world's only oral typhoid vaccine, in North
America. Acambis has a number of other potential travel vaccines in
development. A licence application has been submitted to the US Food and Drug
Administration for a vaccine against yellow fever and clinical trials are being
conducted for vaccines against Japanese encephalitis, travellers' diarrhoea and
dengue fever. Acambis recently became the first company to start human clinical
trials of a vaccine targeting the West Nile virus, which has spread to 45 US
States in the last four years.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on Nasdaq (ACAM). More information is
available at www.acambis.com.



END